[Ip-health] Press release: Pfizer expands generics portfolio

[Suerie Moon]

--
[ Picked text/plain from multipart/alternative ]
Another announcement of a big pharma-Indian generics partnership, see Pfize=
r press release below:
-Suerie
_____________________________
Suerie Moon, MPA
Doctoral Candidate and Giorgio Ruffolo Doctoral Research Fellow
Sustainability Science Program, Center for International Development
Kennedy School of Government, Harvard University
suerie_moon@hksphd.harvard.edu




Pfizer Expands Its Generics Portfolio Through Innovative Licensing
Deals, Increasing Access To Medicines For Billions Worldwide
dateline:
NEW YORK
Pfizer Inc announced today that it has entered into licensing agreements  w=
ith two pharmaceutical companies based in India, strengthening its  positio=
n in emerging markets and significantly expanding its portfolio  of medicin=
es in its Established Products Business Unit.


Off-patent medicines, including branded generics, represent one of the  fas=
test growth segments in the global pharmaceutical market. This is  especial=
ly true in emerging markets where costs and access are primary  drivers of =
off-patent medicine growth.

=E2=80=9CToday=E2=80=99s announcement demonstrates Pfizer=E2=80=99s commitm=
ent to improving the  global public health landscape by making needed quali=
ty medicines - in a  range of disease areas - accessible to underserved pop=
ulations  worldwide,=E2=80=9D said Jeff Kindler, chairman and CEO of Pfizer=
. =E2=80=9CThe  off-patent marketplace worldwide too often suffers from qua=
lity and  supply reliability issues. With our broad established medicines  =
portfolio and our world-class manufacturing capabilities, Pfizer is in  an =
ideal position to supply high-quality medicines at affordable prices  to pe=
ople around the world.=E2=80=9D

Emerging Markets: Reaching New Patients
Pfizer=E2=80=99s expanded agreements with Aurobindo Pharma Ltd. will grow i=
ts  product portfolio within emerging markets to reflect the diverse and  o=
ften unique market dynamics and commercial interests of more than 70  count=
ries.

=E2=80=9CThis deal illustrates the types of innovative partnerships which w=
ill  help to advance Pfizer=E2=80=99s presence in developing markets and en=
hance  access to needed medicines for billions worldwide,=E2=80=9D said Jea=
n-Michel  Halfon, president and general manager of Pfizer=E2=80=99s Emergin=
g Markets  Business Unit. =E2=80=9CThe expansion of our product portfolio f=
rom this deal  provides a foundation for us to commercialize branded generi=
cs based on  patient needs within specific regions.=E2=80=9D

Under the terms of the agreement, Pfizer has acquired rights to 55 solid  o=
ral dose products and 5 sterile injectable products for patients in  more t=
han 70 emerging market countries. These medicines include  antibiotics and =
anti-infectives, and cover a broad range of disease  areas like cardiovascu=
lar and central nervous system disorders. Pfizer  will commercialize the 60=
 products in phases tailoring its approach for  different regions. Financia=
l terms of the deal were not disclosed.

Developed Markets: Expanding Generic  Offerings
Pfizer entered into agreements with Claris Lifesciences Ltd. (=E2=80=9CClar=
is=E2=80=9D)  to commercialize sterile injectable medicines after the produ=
cts are no  longer patent protected, and have lost market exclusivity in No=
rth  America, Europe, Australia and New Zealand. The Claris agreements  adv=
ance Pfizer=E2=80=99s Established Products strategy, which focuses on the  =
commercialization of products where market exclusivity has been lost.  Pfiz=
er=E2=80=99s global annual sales of established products are approximately =
 $10 billion.

Under the terms of the agreements, Pfizer has acquired rights to 15  inject=
able products covering a broad range of therapeutic areas  including anti-i=
nfectives and pain. Financial terms of the deal were not  disclosed.

=E2=80=9CThese agreements advance our goals to expand our steriles portfoli=
o and  provide hospitals and patients with a wide offering of affordable  m=
edicines they can trust. Pfizer=E2=80=99s reputation for high quality and  =
supply reliability is unrivaled in the industry, and this is critical in  t=
he area of sterile injectables,=E2=80=9D said David Simmons, president and =
 general manager of Pfizer=E2=80=99s Established Products Business Unit.
Pfizer also expanded agreements with Aurobindo in developed markets,  addin=
g products in the US and Europe.
To date, 128 non-Pfizer products - 98 solid oral dose and 30 sterile  injec=
tables =E2=80=93 have been added to the Company=E2=80=99s existing diversif=
ied  portfolio of established brands.

Pfizer Inc: Working together for a healthier world=E2=84=A2
Founded in 1849, Pfizer is the world's premier biopharmaceutical company  t=
aking new approaches to better health. We discover, develop,  manufacture a=
nd deliver quality, safe and effective prescription  medicines to treat and=
 help prevent disease for both people and animals.  We also partner with he=
althcare providers, governments and local  communities around the world to =
expand access to our medicines and to  provide better quality health care a=
nd health system support. At Pfizer,  more than 80,000 colleagues in more t=
han 90 countries work every day to  help people stay happier and healthier =
longer and to reduce the human  and economic burden of disease worldwide.

About Pfizer Emerging Markets
Pfizer=E2=80=99s Emerging Markets Business Unit was established in 2009 to =
meet  the diverse medical needs of patients in emerging markets around the =
 world in an innovative, socially responsible and commercially viable  mann=
er. The unit is focused on three strategic priorities: striving to  drive i=
ncremental organic growth, pursuing strategic acquisitions and  partnership=
s and seeking game-changing opportunities for innovation.  Pfizer emerging =
markets spans more than 70 countries, across 20 time  zones with 16,000 col=
leagues and the potential to reach approximately 5  billion people. The bus=
iness unit has identified six priority markets =E2=80=93  China, India, Bra=
zil, Russia, Turkey and Mexico.

About Pfizer=E2=80=99s Established Products
Pfizer=E2=80=99s Established Products Business Unit was created in 2008 to =
 provide underserved patients with affordable medicines characterized by  P=
fizer=E2=80=99s reputation for quality, safety, and innovation. Established=
  products are medicines that have lost patent exclusivity or are close to =
 losing their exclusivity. Pfizer has more than 380 established products  i=
ncluding many familiar brands such as Norvasc, Zoloft and Zithromax.  The E=
stablished Products Business Unit=E2=80=99s broad product portfolio,  capab=
ilities in reformulations and low cost manufacturing position it to  become=
 one of the world=E2=80=99s top pharmaceutical players in the post-LOE  mar=
ket place.